January 2024

Groundbreaking Study Demonstrates 20-Year Remission in Pemphigus Vulgaris Patients Using IVIg Therapy

Uncategorized /

Research published in the prestigious Proceedings of the National Academy of Sciences of the United States of America (PNAS) offers hope for long-term remission in patients with pemphigus vulgaris (PV), a potentially fatal autoimmune blistering disease. Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.

Groundbreaking Study Demonstrates 20-Year Remission in Pemphigus Vulgaris Patients Using IVIg Therapy Read More »

Restoring immune tolerance in pemphigus vulgaris

Uncategorized /

Intravenous immunoglobulin (IVIg), a preparation of polyclonal serum IgG pooled from numerous blood donors, has been used for nearly three decades and is proving to be an efficient treatment for many autoimmune blistering diseases, including pemphigus vulgaris (PV). Despite its widespread use and therapeutic success, its mechanisms of action are not completely understood. Some of its anti-inflammatory and immunomodulatory actions have been studied. In this study, the authors present a twenty-year follow-up of 21 patients with clinical and immunopathological confirmed PV, treated with IVIg as monotherapy, according to an established published protocol.

Restoring immune tolerance in pemphigus vulgaris Read More »